Condition
Stage IV Cancer
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 4 (1)
Trial Status
Unknown1
Enrolling By Invitation1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06883058Not ApplicableEnrolling By Invitation
Caregivers-Patients Support Coping With Advanced-Cancer (CASA) Intervention
NCT03475589Phase 4UnknownPrimary
Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations
NCT00691548Phase 1CompletedPrimary
Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients
Showing all 3 trials